Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Barrett Esophagus-I: Introduction01:21

Barrett Esophagus-I: Introduction

Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more similar...
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Bone tumours].

Der Pathologe·2020
Same author

[Narrow band imaging for evaluation of laryngeal mucosal lesions].

HNO·2017
Same author

Articulating polymethylmethacrylate (PMMA) spacers may have an immunomodulating effect on synovial tissue.

The bone & joint journal·2016
Same author

[Inaugural speech of the congress president of the German Society of Pathology at the 98th annual congress].

Der Pathologe·2014
Same author

[98th Annual Conference of the German Society for Pathology : Berlin, 12-15 June 2014].

Der Pathologe·2014
Same author

BRCA1 promoter methylation is a marker of better response to platinum-taxane-based therapy in sporadic epithelial ovarian cancer.

Journal of cancer research and clinical oncology·2014
Same journal

Autophagy modulation in ulcerative colitis with traditional Chinese medicine: A review.

Pathology, research and practice·2026
Same journal

Ras signalling in infectious disease pathology: Mechanisms, tissue damage, and clinical implications.

Pathology, research and practice·2026
Same journal

CBFβ-SMMHC in inv(16) AML: Fusion biology, RUNX1 dysregulation, and therapeutic targeting of a leukemogenic protein-protein interaction.

Pathology, research and practice·2026
Same journal

Multifactorial pathophysiology of varicocele: Integrating hemodynamic, oxidative, and endocrine mechanisms.

Pathology, research and practice·2026
Same journal

Comparative pathophysiology and pathology of transient ischemic attack, ischemic stroke, and reperfusion injury: Mechanistic and therapeutic perspectives.

Pathology, research and practice·2026
Same journal

Taraxerol targets the HIF1A-NEK6 axis to block TDE-mediated M2 macrophage polarization and inhibits NSCLC progression.

Pathology, research and practice·2026
See all related articles

Related Experiment Video

Updated: May 22, 2026

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

Inflammation and Barrett's carcinogenesis.

A Poehlmann1, D Kuester, P Malfertheiner

  • 1Department of Pathology, Otto-von-Guericke University Magdeburg, Germany. Albert.Roessner@med.ovgu.de

Pathology, Research and Practice
|May 1, 2012
PubMed
Summary
This summary is machine-generated.

Inflammation drives Barrett's esophagus progression to cancer via genetic and epigenetic changes. Understanding these molecular pathways, including oxidative stress and NFκB, is key for new therapies.

More Related Videos

Surgical Models of Gastroesophageal Reflux with Mice
05:19

Surgical Models of Gastroesophageal Reflux with Mice

Published on: August 25, 2015

Diagnosis of Neoplasia in Barrett’s Esophagus using Vital-dye Enhanced Fluorescence Imaging
06:55

Diagnosis of Neoplasia in Barrett’s Esophagus using Vital-dye Enhanced Fluorescence Imaging

Published on: May 11, 2014

Related Experiment Videos

Last Updated: May 22, 2026

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

Surgical Models of Gastroesophageal Reflux with Mice
05:19

Surgical Models of Gastroesophageal Reflux with Mice

Published on: August 25, 2015

Diagnosis of Neoplasia in Barrett’s Esophagus using Vital-dye Enhanced Fluorescence Imaging
06:55

Diagnosis of Neoplasia in Barrett’s Esophagus using Vital-dye Enhanced Fluorescence Imaging

Published on: May 11, 2014

Area of Science:

  • Gastroenterology
  • Oncology
  • Molecular Biology

Background:

  • Barrett's esophagus (BE) is a premalignant lesion where squamous epithelium is replaced by metaplastic columnar epithelium.
  • Esophageal adenocarcinoma (EA) progresses from BE through dysplasia, with inflammation recognized as a key driver of cancer risk.
  • Inflammation's role in Barrett's carcinogenesis involves both genetic alterations and epigenetic modifications, such as promoter methylation leading to gene silencing.

Purpose of the Study:

  • To provide an overview of inflammation-mediated genetic and epigenetic alterations in Barrett's carcinogenesis.
  • To highlight key molecular mediators linking inflammation to cancer development in BE.
  • To emphasize the importance of understanding these pathways for diagnosis, therapy, and prognosis.

Main Methods:

  • Review of current scientific literature on inflammation, Barrett's esophagus, and esophageal adenocarcinoma.
  • Analysis of molecular pathways involving genetic and epigenetic changes.
  • Focus on key mediators such as reactive oxygen species (ROS), NFκB, cytokines, prostaglandins, and microRNAs (miRNAs).

Main Results:

  • Inflammation contributes to Barrett's carcinogenesis through genetic abnormalities and epigenetic silencing of protein expression via promoter methylation.
  • Key mediators identified include ROS, NFκB pathway, inflammatory cytokines, prostaglandins, and specific miRNAs.
  • Oxidative stress and deregulated DNA damage checkpoints are highlighted alongside the NFκB pathway.

Conclusions:

  • Deciphering molecular pathways in Barrett's carcinogenesis is crucial for developing targeted therapies and improving patient outcomes.
  • Understanding the inflammation-cancer connection in BE is essential for advancing diagnosis, treatment, and prognosis.
  • Further research into novel inflammatory mediators and signaling molecules will facilitate the development of pharmaceutical inhibitors.